Bonjour ,
Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.
% complété
%
Company
Rius Medical
35
EQ SCORE L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Rius Medical mission is to make its proprietary highly innovative platform available at year 2 to pharmaceutical and biotech partners - Proprietary cell lines for drug delivery. Engineer stem cells for next generation therapeutics as core business.
Waldachtal, Baden-Württemberg, Germany
Send a message
Anglais
Rius Medical
Anglais
The Elevator Pitch: Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases, like type 1 diabetes by solving the problem of Drug Delivery through reprogramming stem cells.
On offer as Business-to-Business solution to France-based Erytech Pharma, Switzerland-based Orphan Technologies among others is upgraded red blood cells that do more than simply carry oxygen. For example...
The Elevator Pitch: Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases, like type 1 diabetes by solving the problem of Drug Delivery through reprogramming stem cells.
On offer as Business-to-Business solution to France-based Erytech Pharma, Switzerland-based Orphan Technologies among others is upgraded red blood cells that do more than simply carry oxygen. For example Erytech Pharma’s therapeutic product (half-life 29 days) is undergoing clinical Phase III for pancreatic cancer and clinical Phase II for breast cancer. The Business Model is that of a provider/supplier of 120 days lifespan red blood cells against blood donation half-life 29 days red blood cells.
Rius Medical is seeking a 400,000 euro bridge financing for early start July 2021 onwards instead of December 2021 under EIC Pathfinder OPEN grant – supporting the exploration of bold ideas for radically new technologies. Rius Medical proposal has a convincing long-term vision of a radically new technology with a transformative positive effect to the economy and society.
An EXIT opportunity at year 2 for early investors joining this Series A investment round of up to 1 million euro and post-money valuation at 5 million euro will result in EUR 10,5 million financial benefits on TWO products at year 2. So 400,000 euro bridge financing against 8% ownership results in EUR 4,2 million financial benefits on TWO products by December 2022!
-
6
Followers
-
1
Like
Our latest news
[Rius Medical] Protein Therapeutics as Cell Therapy products!
Dear investors,
Everybody wants a healthy and long life. We could live longer, healthier lives, free of degenerative illness. Patients to live free of pain, disease management and life-threatening conditions.
Breakthrough advancement in life sciences: “Invention of mRNA vaccines” case
Well, mRNA vaccines weren’t discovered a year ago—the technology had already been invented, and research had been underway for a decade. The application of mRNA to mitigate Sars-CoV-2 provided a scalable use case, which in some ways catalysed a new era in programmable medicine. mRNA technology is now being investigated for lots of things, including a universal flu vaccine.
That is also the case for Rius Medical with cargo red blood cells as therapeutic. Research had been underway for a century! Alongside the first transfusion in the French army on 16 October 1914, research was underway to have red blood cells do more than simply carry oxygen! Here it is all about finding a scalable use case. Rius Medical has a scalable use case with stem cells therapies. [Please refer to the 10-slides Pitch Deck available on EuroQuity-Rius Medical]
If you as an investor have the fear of missing out on the revolutionary approach, one where venture capital investors and potential pharma partners reveal “a growing interest in the field about cell reprogramming www, then a business partnership with Rius Medical delivers on simplifying these complex therapies.
Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Keep in mind that you the investor in Rius Medical shall receive 20% refund on investment from the German Ministry for Economic Affairs and Climate Protection (BMWK) www. Rius Medical solves the scientific and technical hurdles blocking access to life changing protein therapeutics (enzyme or antigen biologics) by “reprogramming stem cells” into cell therapies.
FYI: Live longer, healthier lives - free of pain, disease management and life-threatening conditions: Aging as a Risk Factor for autoimmune diseases - the immune system in patients with rheumatoid arthritis is prematurely aged by more than 20 years. Rius Medical antigen cargo red blood cells as a vaccine addresses Immune Aging like Rheumatoid Arthritis.
Many thanks and warmest regards,
Denis
Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de
[Rius Medical] Advanced manufacturing - Stem cell-derived cell therapies for million!
Dear investors,
Advanced manufacturing is the use of knowledge and innovative technology to produce complex products. The involvement of regulatory T cells (Tregs) in amyotrophic lateral sclerosis and their therapeutic potential are now considered a promising therapeutic target for neuroprotection in ALS www. Because Harvey Lodish of Massachusetts Institute of Technology and colleagues implemented immune tolerance with red blood cells delivery of protein therapeutics in mouse model of multiple sclerosis and of type 1 diabetes www, thus firmly linking fighting inflammation to fighting Ageing, amyotrophic lateral sclerosis (ALS) and Regulatory T cells therapeutic is at the back of my mind.
Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease or Lou Gehrig's disease, is a neurodegenerative disease that results in the progressive loss of motor neurons that control voluntary muscles. ALS is the most common type of motor neuron disease - think of astrophysicist Stephen Hawking.
Allogeneic cell therapies (CAR NK and encapsulated RBC) under a unique platform technology by my company Rius Medical combine synthetic biology, genetic engineering and stem cells for automation. This enabling technology platform / Advanced manufacturing by Rius Medical has the potential to transform the cell and gene therapy ecosystem and deliver the promise of cell and gene therapy to impact patients’ lives.
Rius Medical brings the best people with the best ideas who are working to make that happen. Rius Medical developing Advanced Manufacturing disrupts the biopharmaceutical industry by overthrowing traditional production models in favour of a new model with synthetic biology, genetic engineering and stem cells combine for automation! Traditional production models have all the cells made by hand in batches, by highly trained scientists sitting in a clean room. That’s not scalable. Rius Medical solving the scalability problem in cell therapy, implements Yamanaka’s discovery in 2006 that opened the way for cell reprogramming. Rather than mimicking the slow natural process of cell culture in cell therapy, Rius Medical triggers specific genes in cells to change how they grow, making the scalability process faster. This approach includes both automation and cell encapsulation of therapeutic cargo - a unique selling proposition among cell reprogramming startups.
Rius Medical technology for Advanced Manufacturing cuts out many labour-intensive steps from the process and speeds up cell production. Cell reprogramming represents a paradigm shift in the way we view biology. Cell reprogramming is an example of synthetic biology, which basically means taking a ‘software’ approach to biology. Rius Medical’s DNA quaternary coding is like Microsoft’s Windows operating system on stem cells! This gives Rius Medical a higher success than traditional methods such as Cambridge USA Rubius Therapeutics with stem cell-derived cell therapies for drug delivery www.
If you as an investor have the fear of missing out on the revolutionary approach, one where venture capital investors and potential pharma partners reveal “a growing interest in the field about cell reprogramming www, then a business partnership with Rius Medical delivers on simplifying these complex therapies.
Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Keep in mind that you the investor in Rius Medical shall receive 20% refund on investment from the German Ministry for Economic Affairs and Climate Protection (BMWK). Rius Medical is developing Advanced Manufacturing to help patients with cancer and other diseases such as type 1 diabetes by solving the problem of drug delivery through stem cell reprogramming.
Many thanks and warmest regards,
Denis
Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de
- slide 1 of 5, currently active
- slide 2 of 5
- slide 3 of 5
- slide 4 of 5
- slide 5 of 5
Team member(s)
Your request has been sent
Join this organization
Your request has been sent
Team member(s)
Our network
Your request has been sent
Join this network
Your message has been sent
Communities
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding
for selected DEEP TECH companies.
2667 Members
A pan-european community to develop awareness-raising and capacity-building for business angels and other early-stage investors.
469 Members
Our history
Start in 31 August 2016
-
31 August 2016
registration with the commercial register of Stuttgart local court under folio HRB 757947
to be continued ...